Michelle Dawson posts

Post published on Twitter/X on 6 Jun 2023 16:18

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov External link integrated into the post Autism terms
Open original post

Information about the link integrated into the post

Clinical trial

Institut de Recherches Internationales Servier, ADIR, a Servier Group company (2018). Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.. ClinicalTrials.gov. Institut de Recherches Internationales Servier.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Institut de Recherches Internationales Servier, ADIR, a Servier Group company (2018). Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.. ClinicalTrials.gov. Institut de Recherches Internationales Servier.

Publication date
4 Oct 2018
Identifier
NCT03715153
Authors
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Institut de Recherches Internationales Servier
Metadata source
clinicaltrials.gov

Abstract

The purpose of this study was to evaluate the efficacity and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

Open source Link to cited source